Growth hormone (GH),
Expression of the c-fos proto-oncogene is rapidly induced by growth hormone (GH) 1 (1, 2) . The Serum Response Element (SRE), an enhancer sequence upstream of the c-fos gene, can mediate transcriptional activation in response to GH (3, 4) . Transcriptional activation via the SRE in response to GH requires the presence of the transcription factors Ternary Complex Factor (TCF) and Serum Response Factor (SRF) at the SRE (4) .
Elk-1 is a member of the TCF family of transcription factors, which also includes SAP-1 and SAP-2/ERP/Net (5, 6) . GH was recently found to stimulate serine phosphorylation of Elk-1 and to stimulate Elk-1-dependent transcriptional activation (4) . Phosphorylation and activation of Elk-1 in response to agents such as serum and ultraviolet light are reported to be mediated by mitogen-activated protein kinase (MAPK) pathways, including extracellular signal-regulated kinases (ERKs) 1 and 2, as well as the stress-induced kinases Jun N-terminal kinase (JNK) and p38 (7) (8) (9) (10) (11) (12) .
The binding of GH to its receptor results in the activation of JAK2 (13) , initiating several signaling cascades, including one in which a SHC-Grb2-SOS complex activates Ras (14) . These events correlate in time with GH-induced activation of Raf, MAPK/ERK kinase (MEK), and ERK1 and -2 (14 -17) . Activation of the ERK pathway by GH raises the possibility that a MAPK pathway may be involved in the regulation of GHpromoted Elk-1 activity. GH has also been documented to stimulate tyrosine phosphorylation of insulin receptor substrate-1 and -2 and concomitant association of both insulin receptor substrate proteins with the 85-kDa regulatory subunit of phosphatidylinositol (PI) 3-kinase (18 -21) . Studies in which the PI 3-kinase inhibitor, wortmannin, interferes with ERK activation suggest a link between PI 3-kinase activation and activation of ERKs (22) (23) (24) (25) . Thus, signaling pathways involving PI 3-kinase may modulate the ERK pathway. This study examines the involvement of Ras, MEK, and ERK1 and -2 in Elk-1-mediated transcriptional activation of c-fos in response to GH and possible sensitivity of this pathway to the PI 3-kinase inhibitor wortmannin. Potential roles for JNK and p38 in mediating GH-induced Elk-1 phosphorylation were also investigated.
EXPERIMENTAL PROCEDURES
Materials-Stocks of 3T3-F442A cells were provided by Dr. H. Green (Harvard University) and Dr. M. Sonenberg (Sloan-Kettering, New York, NY). Chinese hamster ovary (CHO) cells expressing full-length rat GH receptor (GHR-(1-638)) or GHR lacking the C-terminal half of the cytoplasmic domain (GHR-(1-454)) were provided by Drs. Gunnar Norstedt (Karolinska, Stockholm, Sweden) and Nils Billestrup (Hagedorn Laboratory, Gentofte, Denmark) (26) . Recombinant human GH was provided by Lilly. The MEK inhibitor PD098059 was a gift from Dr. A. Saltiel (Parke Davis, Ann Arbor, MI). Wortmannin, the p38 inhibitor SB203580, and anisomycin were purchased from Calbiochem. Sorbitol and phenylmethylsulfonyl fluoride were from Sigma. Leupeptin, aprotinin, and pepstatin were purchased from Boehringer Mannheim, bovine serum albumin (CRG7) from Intergen, and radioisotopes from NEN Life Science Products. Lipofectamine was purchased from Life Technologies, Inc., and luciferin was from Promega. The ECL detection system and Rediprime™ kit were purchased from Amersham Pharmacia Biotech.
Cell Culture and Treatment-3T3-F442A fibroblasts were grown to confluence in Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose and 8 -9% calf serum in an atmosphere of 10% CO 2 /90% air at 37°C. CHO-GHR cells were grown in Ham's-F12 medium containing 0.5 mg/ml G418 and 10% fetal calf serum in an atmosphere of 5% CO 2 , 95% air. All media were supplemented with 1 mM L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin. Prior to treatment, cells were deprived of serum for 16 -18 h in Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose or Ham's F-12 medium containing 1% bovine serum albumin. Cells were preincubated with inhibitor or vehicle (Me 2 SO, 0.2% final concentration, or ethanol) for 1 h prior to treatment with GH or other agents. Unless otherwise indicated, the final concentration of the MEK inhibitor was 100 M, and GH was used at a concentration of 500 ng/ml (22 nM) . This concentration of GH is within the physiological range for circulating rodent GH (27, 28) .
Northern Blot Analysis-Total RNA was isolated as described (29) and subjected to Northern blot analysis using ExpressHyb (CLON-TECH). Prehybridization was performed at 55°C, and hybridization was performed at 68°C. The membranes were probed with cDNAs for mouse c-fos (2), egr-1 (from Dr. L. Lau, University of Illinois, Chicago, IL (30)), junB (from Dr. D. Nathans, John Hopkins, Baltimore MD (31)), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, from Dr. M. Alexander-Bridges, Harvard University), which were labeled with 32 P using a Rediprime kit from Amersham Pharmacia Biotech. Membranes were subjected to autoradiography and/or phosphor imaging, and quantification was performed using Multi-Analyst/PC Molecular Imager software (Bio-Rad).
Luciferase Assay-3T3-F442A cells were stably transfected with a GH-responsive luciferase reporter plasmid driven by the region of the c-fos promoter from Ϫ379 to ϩ1 with a mutation in the CCAAT/enhancer-binding protein binding site (mC/E) (32) (provided by Dr. W. Walton, Moffitt Cancer Center, Tampa, FL) and RSV-neo (from Dr. Nils Billestrup, Hagedorn Laboratory). Pooled clones were generated and maintained as described previously (4) . Cells were deprived of serum overnight and incubated with GH for 4 h. Cell lysates were prepared in reporter lysis buffer (100 mM potassium phosphate, pH 7.8, 0.2% Triton X-100, 1 mM dithiothreitol), and luciferase (Promega) or ␤-galactosidase (Tropix) activity was measured using a Wallac-Berthold Autolumat luminometer or an MGM Opticomp luminometer. Analysis of variance with factorial Scheffe F-test was used to analyze data. A value of p Ͻ 0.05 was considered significant. For control experiments, the plasmids Spi tkluc and RSV-␤-gal were transiently co-transfected into CHO cells expressing GHR-(1-454), and luciferase values were measured as above. Spi tkluc containing eight copies of the spi 2.1 gene (Ϫ147/Ϫ102) upstream of a luciferase reporter gene was constructed as follows: the CAT gene was excised from Spi tkCATAn (from S. Berry, University of Minnesota, Minneapolis, MN (33)) with XhoI/SssT1, leaving the Spi tk backbone. A 2.7-kilobase pair XhoI/SstI fragment containing the luciferase gene was excised from tkluc and then ligated into the Spi tk vector backbone to create Spi tkluc.
Elk-1-mediated Reporter Activation-An expression-reporter system was used to measure Elk-1-mediated transcriptional activation. The expression plasmid Gal4/ElkC (34) encodes a fusion protein containing the Elk-1 transactivation domain fused to the Gal4 DNA binding domain. The control plasmid Gal4 (1-147) (35, 36) encodes amino acids 1-147 of the Gal4 DNA binding domain without an activation domain. The reporter plasmid, 5ϫ Gal/Luc (37) contains five copies of the Gal4 binding site upstream of luciferase cDNA. The plasmids Gal4/ElkC and 5ϫ Gal/Luc were provided by Dr. C. Der (University of North Carolina), and Gal4 (1-147) was received from Dr. M. Ptashne (Harvard University). CHO cells expressing GHR-(1-454) were plated on 35-mm plates and transiently co-transfected using calcium phosphate with 1 g of Gal4/ElkC or Gal4(1-147) DNA, 1 g of Gal/Luc DNA, and 0.1 g of RSV ␤-galactosidase DNA (provided by Dr. M. Uhler, University of Michigan). At 44 -48 h after transfection, cells were deprived of serum for 16 -18 h and treated as indicated. Luciferase assays were performed as described above, and luciferase values from experiments evaluating transcriptional activation were normalized to ␤-galactosidase activity.
Elk-1 Phosphorylation-The cDNA for Elk-1 (from Dr. R. Treisman, Imperial Cancer Research Fund, London) was inserted into the vector pcDNA3 downstream of a CMV promoter to generate CMV-Elk-1 (38) . In experiments evaluating Elk-1 phosphorylation, CMV-Elk-1 or pcDNA3 was transiently transfected into CHO cells expressing GHR-(1-454) using calcium phosphate. Other plasmids were co-transfected with CMV-Elk-1 as follows. The plasmids pZIP-ras(WT), pZIP-ras(15A), and the vector pZIP-NeoSV(x)1 (39, 40) provided by Dr. C. Der (University of North Carolina) were each used at 30 g/100-mm plate. The plasmid encoding MAP kinase phosphatase-1 (MKP-1) (41) was from Dr. J. Pessin (University of Iowa). The CLDN vector, used as a control, was recovered by excising the EcoRI/BamHI fragment containing the MKP-1 sequence. Klenow was then used to generate blunt ends, which were ligated with T4 ligase. Both MKP-1 and CLDN were used at 5 g/100-mm plate. 26 h after transfection, the cells were incubated in medium containing 0.5% fetal calf serum for 16 h and were then incubated in Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose and 1% bovine serum albumin for 5 h prior to treatment as indicated. Cells were lysed and immunoblotted as described.
Antibodies-Polyclonal antibodies against a peptide corresponding to residues 379 -392 of Elk-1 phosphorylated on Ser-383 (␣-P-Elk-1), and polyclonal antibodies against the corresponding nonphosphorylated Elk-1 peptide (␣Elk-1) were purchased from New England Biolabs. Antibodies to dually phosphorylated ERK1 and ERK2 (␣-P-ERK), and dually phosphorylated JNK (␣-P-JNK) were purchased from Promega. According to the manufacturer, the ␣-P-JNK antibodies cross-react with phosphorylated ERK1 and -2. Antibodies to JNK and p38 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies recognizing MEK1 and MAPKAP kinase-2 were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Antibodies to nonphosphorylated ERK1/ERK2 and to MEK1/MEK2 were made as described (42) .
Immunoblotting-Following treatment, cells were washed three times with PBSV buffer (10 mM Tris, 150 mM sodium phosphate, 100 M Na 3 VO 4 , pH 7.4). For analysis of ERKs and Elk-1, cells were scraped in 0.5 ml of 50 mM Hepes, pH 7.0, containing 250 mM NaCl, 0.1% Nonidet P-40, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml each aprotinin and leupeptin. In assays for JNK phosphorylation, cells were lysed in 50 mM Hepes, pH 7.5 containing 150 mM NaCl, 1.5 mM EGTA, 10% glycerol, and 1% Nonidet P-40, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10 g each of aprotinin and leupeptin, 100 mM NaF, and 0.5 mM Na 4 P 2 O 7 . Cell lysates were analyzed on 7.5% polyacrylamide gels for Elk-1, 12% polyacrylamide gels for JNK, and 5-12% gradient polyacrylamide gels for ERK1 and -2. Western blot analysis was performed as described (43) with the indicated antibodies. Enhanced chemiluminescence was used for detection. The apparent M r indicated are based on the migration of prestained molecular weight standards (Life Technologies, Inc.). Membranes were stripped by submerging them in 100 mM ␤-mercaptoethanol, 2% SDS, 62.5 mM TrisHCl, pH 6.7 at 50°C for 30 min with shaking.
Kinase Assays-MAP kinase assays were performed with myelin basic protein as substrate as described previously (16) . MEK activity was measured as described previously (14) . Briefly, cell lysates were incubated for 2 h with an antibody recognizing both MEK1 and -2 (1:1000 dilution). Immune complexes were collected on protein A-agarose during a 1-h incubation with rotation at 4°C; washed three times with 50 mM Tris, pH 7.5, 0.1% Triton X-100, 137 mM NaCl, and 2 mM EGTA; and washed once with 25 mM HEPES, pH 8.0, 0.5 mM EDTA, 0.25% ␤-mercaptoethanol. The immobilized MEK preparation was then incubated with 0.3 g of ERK/sample in kinase buffer (90 mM HEPES, pH 7.5, 5 mM magnesium acetate, and 250 M ATP) for 30 min at 30°C. Triplicate aliquots (10 l) of each sample were incubated with 30 l of kinase buffer containing 20 g of myelin basic protein and 2 Ci of [␥-32 P]ATP for 30 min. Samples were spotted on p81 Whatman filter paper, washed with 1% phosphoric acid, and counted. Assays for p38 utilized its substrate MAPKAP kinase-2. Antibody to MAPKAP kinase-2 (5 g/sample) was used for immunoprecipitation, and MAPKAP kinase-2 activity was measured in an in vitro kinase assay using MAP-KAP kinase-2 substrate peptide (250 mol/sample) as described (44) . JNK activity was assayed using lysates from 3T3-F442A cells that were incubated with glutathione S-transferase-Jun (from B. Margolis, University of Michigan) complexed to glutathione beads for 3 h. Beads were washed twice with wash buffer (140 mM NaCl, 50 mM Tris, pH 8.0, 5 mM EDTA) and 1% Triton-100 and twice with wash buffer without Triton X-100. Beads were incubated for 20 min at 30°C with 10 Ci/sample [␥-
32 P]ATP in 50 mM Tris, pH 7.4, 10 mM MgCl, 1 mM EDTA, 40 M ATP. They were then washed and boiled, and eluted proteins were analyzed by SDS-polyacrylamide gel electrophoresis using a 12% polyacrylamide gel.
RESULTS

Inhibition of the MEK/ERK Pathway Impairs GH-stimulated Transcriptional Activation Mediated by the c-fos
Promoter-GH has been shown to promote c-fos gene expression (2, 45) as well as activation of Ras, Raf, MEK, and ERK1 and -2 in 3T3-F442A fibroblasts (14 -16) . To determine whether the MEK/ERK pathway contributes to GH-stimulated c-fos expression, the MEK inhibitor PD098059 was used to block activation of the MEK/ERK pathway. PD098059 suppresses MEK activation by binding inactive MEK and preventing its phosphorylation by upstream kinases (46) .
The GH-promoted increase in endogenous c-fos expression detected after 30 min (Fig. 1A , lane 2, top) was progressively inhibited by increasing concentrations of MEK inhibitor (Fig.  1A , lanes [3] [4] [5] . When normalized to GAPDH expression, which is unaffected by GH or PD098059 treatment, expression of c-fos was attenuated an average of 31, 69, and 84% with 25, 50, and 100 M PD098059, respectively (n ϭ 2).
To determine whether blocking MEK activation decreases GH-induced activation of the c-fos promoter, PD098050 was added to 3T3-F442A fibroblasts stably transfected with a plasmid (mC/E) containing a GH-responsive c-fos promoter fragment (Ϫ379/ϩ1) upstream of a luciferase reporter gene (Fig.  1B ). GH produced a greater than 4-fold stimulation of reporter expression (Fig. 1B) . Pretreatment of cells with 100 M MEK inhibitor resulted in an 80% reduction in GH-promoted transcriptional activation through the c-fos promoter (Fig. 1B, left) . This degree of reduction corresponds well with the 84% decrease in endogenous c-fos expression observed with 100 M PD098059 (Fig. 1A) . In contrast, PD098059 did not reduce reporter expression mediated by eight tandem copies of the GH-responsive promoter of the spi 2.1 gene (Fig. 1B, right) , indicating some specificity of the MEK inhibitor for the pathway leading to expression of the c-fos promoter. The SRE, which mediates GH-promoted expression of c-fos (3, 4) is also present in the promoters of the GH-responsive genes egr-1 (29) and junB (47) . To assess whether MEK is involved in the expression of SRE-regulated genes other than c-fos, the effect of PD098059 on the expression of egr-1 and junB was examined (Fig. 2) . In 3T3-F442A cells, GH stimulated expression of both egr-1 and junB (Fig. 2, A 
and B, top, lane 2).
In two experiments in which mRNA levels were normalized to GAPDH mRNA levels, expression of egr-1 and junB was inhibited by pretreatment with PD098059 ( Fig. 2, lanes 3-5) . Pretreatment of cells with 50 M PD098059 decreased GH-promoted expression of egr-1 by 35% and junB by 43%, and 100 M PD098059 decreased the expression of egr-1 by 61% and junB by 55%. To verify that PD098059 effectively blocks GH-stimulated activation of MEK and ERK, 3T3-F442A fibroblasts were preincubated with PD098059 for 1 h prior to GH addition (Fig. 3) . The activity of ERK1 and -2 was assessed by Western blot analysis with an antibody (␣-P-ERK) specific for dually phosphorylated, activated ERK1 and ERK2. GH treatment for 5 min increased levels of phosphorylated ERK1 and -2 (Fig. 3A,  top, lanes 4 and 5 versus lanes 2 and 3) . The addition of increasing concentrations of PD098059 progressively lowered levels of dually phosphorylated ERK1 and ERK2 in GH-treated cells (Fig. 3A, top, lanes 6 -11) . In five separate experiments, ERK phosphorylation was inhibited 47% with 25 M, 77% with 50 M, and 101% with 100 M PD098059. Levels of nonphosphorylated ERK were not affected by treatment with PD098059 (lane 1 versus lane 2, bottom).
To provide additional evidence that the MEK inhibitor attenuates GH-promoted MAP kinase activity, MAP kinase activity was directly examined in 3T3-F442A lysates using an in vitro kinase assay with myelin basic protein as substrate. GH increased MAP kinase activity almost 2-fold (Fig. 3B) . PD098059 reduced GH-stimulated MAP kinase activity at concentrations (25, 50 , and 100 M) that inhibit GH-induced phosphorylation of ERK1 and ERK2 (Fig. 3B) . PD098059 decreased basal MAP kinase activity slightly (8%, data not shown). MEK activity was measured using MEK that was immunoprecipitated from 3T3-F442A cell lysates with antibodies that recognize MEK1 and MEK2 (Fig. 3C) . MEK immunoprecipitates were used in an in vitro kinase assay containing a glutathione S-transferase-ERK fusion protein (14) and myelin basic protein. GH stimulated an 11-fold increase in MEK activity, which was reduced approximately 75% when cells were pretreated with 50 or 100 M MEK inhibitor (Fig. 3C) . In Fig. 3C , the MEK inhibitor failed to abrogate MEK activity completely. It seemed possible that MEK2 activity might account for the residual activity, although 10-fold higher concentrations of PD098059 are needed to inhibit MEK2 than MEK1 (46) . However, results similar to those shown in Fig. 3C were obtained using antibodies specific for MEK1, suggesting that the residual MEK activity is not due to MEK2. Wortmannin Impairs GH-stimulated Expression and Promoter Activation of c-fos-Wortmannin, a potent PI 3-kinase inhibitor, has been demonstrated to interfere with GH-induced ERK activation, presumably via a mechanism involving PI 3-kinase (25, 48) . If ERKs mediate GH-promoted c-fos expression, then wortmannin would also be expected to inhibit GHinduced c-fos expression. In 3T3-F442A cells, expression of c-fos mRNA (normalized to GAPDH mRNA levels) was reduced by 41% with 100 nM wortmannin and by 84% with 500 nM wortmannin (Fig. 4A, lanes 3 and 4 versus lane 2) . Wortmannin inhibited GH-induced c-fos promoter-mediated reporter expression by 64% (250 nM) and 86% (500 nM) (Fig. 4B) . Concentrations of wortmannin of 100 and 500 nM inhibited GH-induced ERK phosphorylation (Fig. 4C, top, lanes 4 and 5 versus lane 2 (4) demonstrated that GH stimulates Elk-1-mediated transcriptional activation of a luciferase reporter gene in CHO cells stably expressing fulllength GHR-(1-638) or truncated GHR-(1-454). GH induces c-fos mRNA and stimulates transcriptional activation via the SRE to comparable extents in both cell lines (29) . Unless otherwise indicated, CHO cells expressing GHR-(1-454) (referred to hereafter as CHO-GHR cells) were used in the present study. To examine whether blocking ERK activity alters the ability of Elk-1 to mediate transcriptional activation in response to GH, CHO-GHR cells transfected with plasmids encoding a Gal-Elk/ Gal-luciferase expression-reporter system (see "Experimental Procedures") were treated with PD098059 prior to GH (Fig. 5,  left panel) . GH alone stimulated Elk-1-mediated transcriptional activation in CHO-GHR cells, as expected. Incubation with PD098059 prior to GH treatment blocked GH-stimulated luciferase activity (Fig. 5, left panel) , indicating that GH-stimulated Elk-1-dependent gene expression requires MEK activation. Similar results were observed in CHO cells stably expressing full-length GHR-(1-638) (data not shown). In control experiments, GH failed to stimulate Elk-1-mediated reporter expression in cells transfected with a plasmid (Gal4 (1-147) ) encoding the Gal4 DNA binding domain lacking an activation domain (Fig. 5, right panel) , indicating that the Elk-1 transcriptional activation domain is required for GH-stimulated reporter expression.
Inhibition of the MEK/ERK Pathway Blocks GH-stimulated Activation of Elk-1-Previous studies
GH-stimulated Phosphorylation of Elk-1 Is Blocked by the MEK Inhibitor, Dominant
Negative Ras, and MAPK Phosphatase-1-Since phosphorylation of Elk-1 is thought to be important in Elk-1 activation, the ability of the MEK inhibitor to block GH-stimulated Elk-1 phosphorylation was examined. CHO-GHR cells were transiently transfected with a plasmid (CMV-Elk-1) encoding Elk-1, and phosphorylated Elk-1 was detected by immunoblotting with antibodies against a synthetic Elk-1 peptide phosphorylated on serine 383 (Fig. 6) . The stimulation of Elk-1 phosphorylation by GH was concentrationdependent from 5 to 500 ng/ml (0.22-22 nM). The appearance of multiple bands with decreased mobility in the lysates of GHtreated cells is consistent with Elk-1 being phosphorylated on multiple sites (upper panel). Pretreatment of cells with PD098059 (100 M) obliterated all bands recognized by the ␣-P-Elk-1 antibodies at all concentrations of GH (Fig. 6, lanes  5-8) , consistent with a role for ERKs in GH-stimulated Elk-1 phosphorylation. Nonphosphorylated Elk-1 protein levels were comparable under all conditions (Fig. 6, lower panel) .
To demonstrate further the role of the signaling pathway involving Ras, MEK, and ERK in GH-stimulated Elk-1 phosphorylation, additional steps of this MAPK pathway were modulated. Interfering with MAPK activation by co-expressing MKP-1 with CMV-Elk-1 prevented the appearance of the bands 1 and 2) prior to the addition of GH for 15 min. ERK phosphorylation was measured in whole cell lysates by immunoblotting as described for Fig. 3 .
recognized by ␣-P-Elk-1 in response to GH (Fig. 7A, top, lane 4) , whereas GH clearly induced bands representing phosphorylated Elk-1 in the absence of MKP-1 (Fig. 7A, top, lane 2) . Dominant negative Ras (15A) also decreased GH-stimulated Elk-1 phosphorylation compared with vector (pZIP-Neo) alone (Fig. 7B, top, lane 4 versus lane 2) . Conversely, overexpression of wild-type Ras elevated levels of protein recognized by ␣-PElk-1 in both GH-and vehicle-treated cells. (Fig. 7B, upper  panel, lanes 5 and 6) . Elk-1 protein was present in all conditions (Fig. 7, A and B, lower panels) . In lysates from GH-treated cells analyzed with ␣Elk-1, a slower migrating band is observed that comigrates with the band recognized by ␣-P-Elk-1 (Fig. 7,  A and B, lane 2, bottom versus top) . This slower migrating band is likely to represent Elk-1 phosphorylated on serine 383 and is absent in lysates from cells transfected with MKP-1 or dominant negative Ras. These data are consistent with observations with PD098059 and together support a role for Ras and MAP kinase activation in GH-stimulated Elk-1 phosphorylation.
JNK and p38 Kinase Do Not Mediate GH-stimulated Phosphorylation and Activation of Elk-1-Although ERK1 and ERK2 appear to be the major Elk-1 kinases regulated by growth factors (10, 49) , JNK and p38 kinase are also capable of activating Elk-1 in response to cellular stresses such as ultraviolet light and interleukin-1 (8, 11) . To determine whether GH regulates JNK and as a step toward determining whether JNK contributes to GH-stimulated transcriptional activation via Elk-1, JNK activity was assayed in 3T3-F442A cells treated with GH. JNK phosphorylation was measured using an antibody (␣-P-JNK) that recognizes dually phosphorylated, activated p54 and p46 JNK. In 3T3-F442A fibroblasts, GH treatment for 10, 20, or 30 min failed to stimulate phosphorylation of p54 or p46 JNK (Fig. 8A, top, lanes 4 -6) . GH also failed to induce JNK phosphorylation in CHO-GHR cells (data not shown). The capability of ␣-P-JNK to detect phosphorylation of JNK was verified using anisomycin, which stimulated phosphorylation of both p46 and p54 JNK in 3T3-F442A cells (Fig.  8A, lane 7) . Due to cross-reactivity of the ␣-P-JNK antibody with phosphorylated ERKs, bands that co-migrate with phosphorylated ERK1 and -2 (data not shown) were observed, most notably in lysates from cells treated with GH for 10 min (Fig.  8A, lane 4) . To confirm that GH did not stimulate JNK activity in 3T3-F442A cells, lysates from GH-treated cells were also tested for their ability to phosphorylate glutathione S-transferase-Jun. Clearly, GH failed to induce JNK activity (Fig. 8B,  lanes 4 -6) , while anisomycin (lane 7) was effective. The failure of GH to stimulate JNK activity suggests that JNK is unlikely to play a role in GH-promoted Elk-1-mediated gene expression.
To investigate the possible contribution of p38 kinase activity to GH-stimulated Elk-1 phosphorylation and activation, CHO-GHR cells transfected with CMV-Elk-1 were pretreated with the specific p38 inhibitor, SB203580. The p38 inhibitor (10 M) failed to reduce GH-stimulated Elk-1 phosphorylation when compared with vehicle-treated cells and may have increased it (Fig. 9B, lane 6 versus lane 2) . In the same experiment, PD098059 blocked GH-promoted Elk-1 phosphorylation completely (lane 4). Furthermore, the p38 inhibitor failed to block the ability of Elk-1 to mediate transcriptional activation in response to GH (data not shown). To determine whether GH regulates p38, the activity of the p38 substrate, MAPKAP kinase-2, was measured in 3T3-F442A cells (Fig. 9B) . GH induced a modest 0.6-fold increase in MAPKAP kinase-2 activity, compared with the more robust (4-fold) stimulation by anisomycin (data not shown), which is known to stimulate p38 kinase activation. The modest increase in GH-induced p38 kinase activity was blocked completely when cells were preincubated with 10 M of the p38 inhibitor SB203580 (Fig. 9B) . In contrast, the MEK inhibitor did not reduce the slight GHpromoted increase in MAPKAP kinase-2 activity in two independent experiments (data not shown). Thus, GH stimulates a modest increase in p38-dependent MAPKAP kinase-2 activity, and this activity is not sensitive to MEK inhibition. Although the p38 inhibitor blocked the modest GH-induced increase in p38 activity, it failed to attenuate GH-induced phosphorylation of Elk-1, suggesting that GH-promoted p38 activity is not likely to play a role in GH-stimulated Elk-1 phosphorylation. These data are consistent with the hypothesis that MEK-activated ERK1 and -2 are the key MAPKs that mediate GH-induced Elk-1 phosphorylation and activation.
DISCUSSION
Activation of Ras, MEK, and ERK1 and -2 Mediates GHstimulated Phosphorylation and Activation of Elk-1-This
study demonstrates that GH-stimulated phosphorylation of Elk-1 and Elk-1-dependent gene expression are mediated by a pathway involving activation of Ras, MEK, and ERK1 and -2. Overexpression of a dominant negative Ras mutant reduces GH-stimulated Elk-1 phosphorylation, suggesting that Ras plays a role in Elk-1 phosphorylation. Conversely, overexpression of wild-type Ras elevates basal and GH-induced phosphorylation of Elk-1. Since activation of Ras leads to activation of the MEK/ERK pathway (50, 51) , these data are consistent with the idea that Ras acts upstream of MEK and ERK to participate in GH-stimulated phosphorylation of Elk-1. However, treatment with GH increased the phosphorylation of Elk-1 in cells overexpressing wild-type Ras, suggesting that other signaling molecules may also contribute to activation of a MEK/ ERK pathway in response to GH.
Inhibition of MEK or ERK activity blocks GH-promoted Elk-1 phosphorylation and activation completely. The MEK inhibitor PD098059 was used as one tool for examining the role of MEK and ERK in GH signaling, because it specifically inhibits the phosphorylation of inactive MEK by upstream kinases while failing to inhibit directly the activation of other signaling molecules (46) such as p38, JNK, ERK2, MAPKAP kinases 1 and 2, Raf (an activator of MEK), MKK4 (a JNK kinase), and protein kinase C (implicated in GH-stimulated c-fos expression) (2, 47, 52). GH-stimulated phosphorylation and activation of Elk-1 was blocked effectively by the MEK inhibitor (100 M). Since the MEK inhibitor also abrogated GH-induced ERK activity, these data support the involvement of both MEK and ERKs in the phosphorylation and activation of Elk-1 in response to GH. Furthermore, dephosphorylation of ERKs with the ERK-specific phosphatase, MKP-1, also successfully blocks Elk-1 phosphorylation, substantiating the role of ERKs in the phosphorylation of Elk-1. Together, these data support a model in which activation by GH of a Ras/MEK/ERK cascade leads to ERK-mediated phosphorylation and activation of Elk-1.
Recent evidence suggests that the EGFR may contribute to JAK2-mediated activation of the MEK/ERK pathway in response to GH (53) . The present study does not address specifically the mechanisms upstream of Ras by which GH stimulates activation of the MEK/ERK pathway. Rather, the data presented here clearly show that the MEK/ERK pathway is essential for the activation of downstream end points such as Elk-1 phosphorylation and transcriptional activation and expression of early response genes in response to GH. However, results presented here indicate that the effects of GH on Elk-1 phosphorylation and c-fos expression can occur independently of EGFR-mediated signaling, because CHO-GHR cells, in which these responses were studied, lack the EGFR. In 3T3-F442A cells, which have both endogenous GHR and EGFR, it is possible that EGFR-mediated signaling contributes to GHstimulated activation of the MEK/ERK pathway. Future investigation of the varying contributions of GHR and EGFR signaling to GH-stimulated activation of the MEK/ERK pathway as FIG. 7 . GH-stimulated Elk-1 phosphorylation is altered by MAP kinase phosphatase and Ras. CHO-GHR cells were transiently co-transfected with CMV- Elk-1 (all lanes) and one of the following. A, irrelevent vector, pcDNA3 (Control, lanes 1 and 2) or CMV-MKP-1 (MKP-1, lanes 3 and 4) ; B, pZIP-NeoSV(x)1 (Neo, lanes 1 and 2) , dominant negative Ras, pZIP-ras(15A) (D/N Ras, lanes 3 and 4) , or wild-type Ras, pZIP-ras(WT) (wt Ras, lanes 5 and 6). 36 h after transfection, cells were deprived of serum for 5 h, and GH (A , lanes 2 and 4; B, lanes 2, 4, and  6) or vehicle (A, lanes 1 and 3; B, lanes 1, 3, and 5) were added for 30 min. Whole cell lysates were analyzed as described for Fig. 6 . Lanes 1-4 were exposed to x-ray film for a longer period of time than lanes 5 and 6. Similar results were observed in three experiments. well as downstream gene expression may yield insights into how cross-talk occurs between various signaling pathways.
JNK and p38 Kinase Do Not Mediate GH-stimulated Phosphorylation and Activation of Elk-1-Among the MAPKs, both JNK and p38 MAPKs are also reported to phosphorylate Elk-1 in several cell types (7, 9, 11, 12) . JNK and p38 are thought to be activated primarily in response to cellular stresses such as inflammatory cytokines, heat and chemical shock, bacterial endotoxin, and ischemia (reviewed in Ref. 54 ). However, activation and integration of MAP kinase signaling pathways utilizing JNK, p38, and ERK are complex and dependent on many factors such as cell type and the nature of the stimulus (54). In 3T3-F442A cells, GH failed to stimulate phosphorylation of JNK or JNK activity as measured by the phosphorylation of its substrate, Jun. Although GH produced a slight (0.6-fold) increase in p38-dependent MAPKAP kinase-2 activity, the inability of the p38 inhibitor SB203580 to attenuate GH-promoted Elk-1 phosphorylation or Elk-1-mediated transcriptional activation makes it highly unlikely that p38 contributes to GHstimulated Elk-1 activation. These data do not preclude possible involvement of p38 in other GH-dependent events. Together, the present data are consistent with the view that JNK and p38 do not contribute significantly to GH-promoted phosphorylation and activation of Elk-1. Further, because the MEK inhibitor PD098059 does not inhibit JNK or p38 activity directly in vitro, the complete block of GH-induced Elk-1 phosphorylation and activation observed with PD098059 suggests that ERK1 and -2 are the primary, and perhaps the sole, Elk-1 kinases activated in response to GH.
ERK1 and -2 Mediate Activation of SRE-regulated Genes in
Response to GH-The present data suggest that GH-stimulated c-fos expression is mediated by ERK activation of transcription factors bound to the c-fos SRE. The c-fos SRE includes a CArG box, which binds SRF, and an Ets motif, which binds TCF family members (55) . In GH-treated cells, Elk-1 and SRF are both present in the complex bound to the c-fos SRE (4). Binding of SRF to the CArG box is thought to recruit TCF family members, such as Elk-1, to the Ets motif sequence (55) . Thus, GH fails to stimulate transcriptional activation via a c-fos promoter fragment or the SRE alone when either the SRF or TCF binding sites are mutated (4, 56) . Other TCF family members such as SAP-1a and SAP-2/ERP/NET can bind to the Ets motif (6) . Both of these TCFs are reported to mediate transcriptional activation when activated by ERK2, although SAP-1a has also been shown to be activated by the stress-induced MAPKs, JNK and p38 (6, 57, 58) . Future investigation of the effects of GH and other agents on the binding, phosphorylation, and activation of SAP-1a and SAP-2/ERP/NET may provide additional insight into how TCF proteins regulate gene expression in a stimulus-specific manner and whether they play a role in transcriptional activation via the SRE in response to GH .
Activation of ERK1 and -2 by GH may facilitate binding of SRF to the SRE. SRF can be phosphorylated by an ERK-dependent mechanism involving p90 rsk (59 -63) ; SRF phosphorylation is thought to facilitate binding of SRF to the SRE (60, 61) . GH stimulates activation of p90 rsk in 3T3-F442A cells (64) , but it is not currently known whether GH promotes phosphorylation of SRF. Although Elk-1 and SRF are constitutively bound to the SRE in 3T3-F442A cells, GH rapidly and transiently increases further binding of both proteins (4). More work is needed to determine whether ERK-dependent binding of SRF is necessary for transcriptional activation through the SRE in response to GH.
The model of GH-stimulated activation of SRE-containing genes mediated by ERK1 and -2 is supported by the observation that attenuation of ERK activation with the MEK inhibitor also impaired GH-stimulated expression of egr-1 and junB. Two of the four SRE sequences upstream of egr-1 mediate transcriptional activation in response to human granulocytemacrophage colony-stimulating factor, mouse interleukin-3, urea, and antigen receptor cross-linking (65) (66) (67) . The induction of egr-1 transcription by these agents requires the Ets sequences adjacent to the CArG boxes (66, 67) . Moreover, the expression of egr-1 is thought to be ERK-dependent in response to urea and insulin (68, 69) and to involve activation of JAK2 and Ras in the case of human granulocyte-macrophage colonystimulating factor (65) . The junB enhancer regions also contain two SREs that mediate transcriptional activation in response FIG. 9 . GH-induced p38 activity does not contribute to GHstimulated Elk-1 phosphorylation. A, CHO-GHR cells were transiently transfected with the plasmid CMV-Elk-1 (all lanes). 36 h later, cells were deprived of serum for 6 h. Me 2 SO (lanes 1 and 2) , MEK inhibitor PD098059 (MI, 100 M, lanes 3 and 4) , or p38 inhibitor SB203580 (10 M, lanes 5 and 6) was added for the final hour. Cells were treated with GH or vehicle for an additional 30 min. Whole cell lysates were analyzed for the presence of phospho-Elk-1 or Elk-1 by immunoblotting as described for Fig. 6 . Similar results were observed in two experiments. B, 3T3-F442A cells were preincubated with Me 2 SO or a 10 M concentration of the p38 inhibitor SB203580 for 1 h and then treated for 20 min with vehicle (C, solid bars) or GH (hatched bars). Cell lysates were then harvested and assayed for MAPKAP kinase-2 activity. MAPKAP kinase-2 activity is expressed relative to that in control cells (control ϭ 1, solid bar) . Bars show the means ϩ S.E. for three separate experiments. The stimulation of MAPKAP kinase-2 activity by GH is significant (p Ͻ 0.01), and the activity observed with the p38 inhibitor in the absence and presence of GH did not differ significantly from that in control Me 2 SO-treated cells.
to serum (70, 71) . One of the junB SREs is similar to the c-fos SRE (70, 71) , but it is not yet clear whether Ets sites play a role in transcriptional activation through the junB SREs. Further, Ets-independent transcriptional activation through the c-fos SRE can be stimulated by treatment with lysophosphatidic acid (72) , indicating that multiple mechanisms exist for stimulation of c-fos transcription via the SRE. It will be of interest to determine whether ERK-mediated Elk-1 activation of transcription through the SRE is the only pathway by which GH induces expression of SRE-regulated genes.
The MEK inhibitor may block GH-stimulated transcriptional activation of c-fos, egr-1, and junB in part by inhibiting the ERK-dependent activation of transcriptional complexes other than the SRE in the promoters of these genes. For example, previous work has shown that GH induces tyrosyl phosphorylation and binding of STATs 1 and 3 to the Sis-inducible element in the c-fos promoter (73) (74) (75) . Serine phosphorylation, possibly mediated by ERKs, is thought to contribute to STATmediated transcriptional activation (76 -79) . While these studies suggest that STAT-mediated transcriptional activation may be susceptible to MEK inhibition, the role of STATs in GHstimulated activation of c-fos is still being explored.
Role of PI 3-Kinase in GH-stimulated ERK Activation-GHinduced signaling through the Ras/MEK/ERK cascade may be modulated by the activity of other signaling molecules, such as those sensitive to wortmannin. This study demonstrates that wortmannin interferes with GH-stimulated ERK activation as well as downstream transcriptional activation of c-fos. GH promotes phosphorylation of Insulin Receptor Substrate-1 and -2 and association of these proteins with the Src homology 2 domain of the 85-kDa regulatory subunit of PI 3-kinase, resulting in activation of PI 3-kinase (18, 19, 21) . The PI 3-kinase inhibitor wortmannin has been used to implicate PI 3-kinase in GH-stimulated lipid synthesis (25) and activation of p70 S6K (80) . In addition, GH-promoted ERK activation is inhibited in wortmannin-treated cells (23, 48, 80) , as observed here. The data here demonstrate that GH-stimulated expression of c-fos and c-fos promoter function is blocked by wortmannin. Such inhibition is consistent with a requirement for ERK activation in GH-promoted transcription of c-fos and raises the possibility that a member of the PI 3-kinase family may participate in GH-induced c-fos expression.
In summary, the data presented support a model in which activation by GH of the Ras/MEK/ERK cascade promotes Elk-1 phosphorylation and Elk-1-mediated transcriptional activation of gene expression. When the Ras/MEK/ERK pathway was blocked, GH failed to stimulate phosphorylation and activation of Elk-1. Since GH did not activate JNK and produced only a slight increase in p38 activity, which did not contribute significantly to GH-stimulated Elk-1 phosphorylation or activation, JNK and p38 are not likely to activate Elk-1 in response to GH. The Ras/MEK/ERK cascade was found to mediate GH-induced expression of several SRE-regulated genes, including c-fos, egr-1, and junB. A wortmannin-sensitive molecule, possibly PI 3-kinase, may regulate ERK activation and subsequent transcriptional activation of c-fos in response to GH. Knowledge of the mechanisms by which GH promotes changes in gene expression provides a foundation for exploring the many functions of this major regulator of growth and differentiation.
